


Claims

1. A compound of Formula (I)




- 5 or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or said salt, wherein:

each R^1 is independently H or F;

- 10 R² is H, (C₁-C₄)alkyl, hydroxy(C₁-C₄)alkyl, (C₁-C₄)alkoxy(C₁-C₄)alkyl or (C₁-C₄)alkyl substituted by one, two or three F;

each R³ is independently H, F, (C₃-C₅)cycloalkyl, (C₁-C₄)alkyl or (C₁-C₄)alkyl substituted by one, two or three F; or both R³ taken together with the carbon atom to which they are attached form (C₃-C₅)cycloalkyl;




- R⁴ is selected from , wherein each heterocycle is optionally substituted by one or two substituents independently selected from oxo, (C₁-C₄)alkyl, hydroxy(C₁-C₄)alkyl and (C₁-C₄)alkyl substituted by one, two or three F; and

R⁵ and R⁶ are independently H; halogen; OH; CN; (C₁-C₆)alkyl; hydroxy(C₁-C₆)alkyl; (C₁-C₄)alkoxy(C₁-C₆)alkyl; (C₁-C₆)alkyl substituted by one, two or three F; (C₁-C₆)alkoxy; or (C₁-C₆)alkoxy substituted by (C₁-C₄)alkoxy.


25

2. A compound according to claim 1, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or said salt, wherein each R¹ is H.
- 5 3. A compound according to claim 1 or claim 2, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or said salt, wherein R² is H or (C₁-C₄)alkyl.
4. A compound according to claim 3, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or said salt, wherein R² is methyl.
- 10 5. A compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or said salt, wherein each R³ is independently H, F or (C₁-C₄)alkyl.
- 15 6. A compound according to claim 5, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or said salt, wherein each R³ is independently H, F or methyl.
- 20 7. A compound according to claim 6, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or said salt, wherein one R³ is H and the other R³ is methyl.
- 25 8. A compound according to claim 7 of Formula (Ia)




or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or said salt.

9. A compound according to any one of claims 1 to 8, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or said salt, wherein R^4 is




optionally substituted by one or two substituents independently selected from oxo, (C₁-C₄)alkyl and hydroxy(C₁-C₄)alkyl.

10. A compound according to claim 9, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or said salt, wherein R^4 is



11. A compound according to claim 10, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or said salt, wherein R^4 is



12. A compound according to any one of claims 1 to 11, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or said salt, wherein R^5 and R^6 are independently H; halogen; OH; CN; (C₁-C₃)alkyl; hydroxy(C₁-C₃)alkyl; (C₁-C₃)alkoxy(C₁-C₃)alkyl; (C₁-C₃)alkyl substituted by one, two or three F; (C₁-C₃)alkoxy; or (C₁-C₃)alkoxy substituted by (C₁-C₃)alkoxy.

13. A compound according to claim 12, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or said salt, wherein R^5 is H, halogen, CN, (C₁-C₃)alkyl, (C₁-C₃)alkoxy or (C₁-C₃)alkoxy substituted by (C₁-C₃)alkoxy.

14. A compound according to claim 12 or claim 13, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or said salt, wherein R⁶ is H; halogen; OH; CN; (C₁-C₃)alkyl; hydroxy(C₁-C₃)alkyl; (C₁-C₃)alkoxy(C₁-C₃)alkyl; (C₁-C₃)alkyl substituted by one, two or three F; or (C₁-C₃)alkoxy.
15. A compound according to claim 1, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or said salt, selected from:
- (S)-*N*-methyl-*N*-(6-methyl-2-((4a*S*,5a*R*)-5a-methyl-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazol-3-yl)-1*H*-benzo[d]imidazol-5-yl)-2-morpholinopropanamide;
- (*R*)-*N*-methyl-*N*-(2-((4a*S*,5a*R*)-5a-methyl-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazol-3-yl)-1*H*-benzo[d]imidazol-5-yl)-2-(tetrahydro-2*H*-pyran-4-yl)propanamide;
- (*R*)-*N*-(7-fluoro-2-((4a*S*,5a*R*)-5a-methyl-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazol-3-yl)-1*H*-benzo[d]imidazol-5-yl)-*N*-methyl-2-(tetrahydro-2*H*-pyran-4-yl)propanamide;
- (S)-*N*-(7-fluoro-2-((4a*S*,5a*R*)-5a-methyl-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazol-3-yl)-1*H*-benzo[d]imidazol-5-yl)-*N*-methyl-2-morpholinopropanamide;
- (S)-*N*-ethyl-*N*-(7-fluoro-2-((4a*S*,5a*R*)-5a-methyl-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazol-3-yl)-1*H*-benzo[d]imidazol-5-yl)-2-morpholinopropanamide;
- (S)-*N*-(6,7-difluoro-2-((4a*S*,5a*R*)-5a-methyl-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazol-3-yl)-1*H*-benzo[d]imidazol-5-yl)-*N*-methyl-2-morpholinopropanamide;
- (S)-*N*-(6,7-difluoro-2-((4a*S*,5a*R*)-5a-methyl-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazol-3-yl)-1*H*-benzo[d]imidazol-5-yl)-*N*-ethyl-2-morpholinopropanamide;
- (S)-*N*-(7-fluoro-6-methyl-2-((4a*S*,5a*R*)-5a-methyl-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazol-3-yl)-1*H*-benzo[d]imidazol-5-yl)-*N*-methyl-2-morpholinopropanamide; and

(S)-*N*-methyl-*N*-(7-methyl-2-((4a*S*,5a*R*)-5a-methyl-1,4,4a,5,5a,6-hexahydrocyclopropa[*f*]indazol-3-yl)-1*H*-benzo[*d*]imidazol-5-yl)-2-morpholinopropanamide.

16. The compound according to claim 15 which is (S)-*N*-methyl-*N*-(6-methyl-2-((4a*S*,5a*R*)-5a-methyl-1,4,4a,5,5a,6-hexahydrocyclopropa[*f*]indazol-3-yl)-1*H*-benzo[*d*]imidazol-5-yl)-2-morpholinopropanamide, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or said salt.

10

17. The compound according to claim 15 which is (R)-*N*-methyl-*N*-(2-((4a*S*,5a*R*)-5a-methyl-1,4,4a,5,5a,6-hexahydrocyclopropa[*f*]indazol-3-yl)-1*H*-benzo[*d*]imidazol-5-yl)-2-(tetrahydro-2*H*-pyran-4-yl)propanamide, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or said salt.


15

18. The compound according to claim 16 which is (S)-*N*-methyl-*N*-(6-methyl-2-((4a*S*,5a*R*)-5a-methyl-1,4,4a,5,5a,6-hexahydrocyclopropa[*f*]indazol-3-yl)-1*H*-benzo[*d*]imidazol-5-yl)-2-morpholinopropanamide, or a hydrate thereof.

19. The compound according to claim 18 which is (S)-*N*-methyl-*N*-(6-methyl-2-((4a*S*,5a*R*)-5a-methyl-1,4,4a,5,5a,6-hexahydrocyclopropa[*f*]indazol-3-yl)-1*H*-benzo[*d*]imidazol-5-yl)-2-morpholinopropanamide, dihydrate.

20

20. The compound according to claim 16 which is



25

21. A pharmaceutical composition comprising a compound according to any one of claims 1 to 20 and a pharmaceutically acceptable excipient.

22. A pharmaceutical composition according to claim 21 adapted for topical administration.
23. A pharmaceutical composition according to claim 21 or claim 22 including one or
5 more additional therapeutic agents.
24. A compound according to any one of claims 1 to 20 for use as a medicament.
25. A compound according to any one of claims 1 to 20 for use in the treatment of a
10 disorder for which an ITK inhibitor is indicated.
26. A compound for use according to claim 25 wherein the disorder for which an ITK inhibitor is indicated is a dermatological disorder.
- 15 27. A compound for use according to claim 26 wherein the dermatological disorder is dermatitis.
28. A compound for use according to claim 27 wherein the dermatitis is atopic dermatitis.
20
29. Use of a compound according to any one of claims 1 to 20 for the preparation of a medicament for the treatment of a disorder for which an ITK inhibitor is indicated.
- 25 30. A method of treating a disorder in a human or animal for which an ITK inhibitor is indicated, comprising administering to said human or animal a therapeutically effective amount of a compound according to any of claims 1 to 20.